West Pharma Q2 net sales $723.6M (+37.3%), EPS $2.47 (+104%); raises full-year guidance

WEST PHARMACEUTICAL SERVICES INC

2021-Q2 EPS reported $4.47 revenue$1,394,300,000

Net sales $723.6M, up 37.3% (organic +30.6%); reported diluted EPS $2.47, up 104%.
Adjusted diluted EPS $2.46, up 97%; Proprietary Products segment sales up 47%, driven by HVP components.
Raises FY2021 net sales guidance to $2.760-$2.785B (from $2.630-$2.655B) and adjusted EPS to $8.05-$8.20 (from $6.95-$7.10).
Strong demand from COVID-19 vaccines and base business; new capital spending tranche for HVP capacity expansion in 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.